Abstract: Churg-Strauss syndrome is a rare systemic vasculitis characterized by asthma and other allergy symptoms as well as eosinophilia and necrotizing vasculitis involving small and medium-sized vessels. Its prevalence in the general population ranges from 1-3 cases per million a year, varying according to the population studied. The authors describe a case of a female patient affected by the disease with important systemic manifestations and not very florid skin lesions.
INTRODUCTION
Churg-Strauss syndrome (CSS), or eosinophilic granulomatosis with polyangiitis, is a rare systemic vasculitis characterized by asthma and other allergic symptoms, besides eosinophilia and necrotizing vasculitis of small and medium vessels. 1 The prevalence in the general population is of 1-3 cases/million, and varies according to the population studied. The condition affects both sexes with the same frequency, in the third and fifth decades of life.
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CASE REPORT
A 53-year-old female patient presented at the dermatology service with history of fever, slightly pruritic lesions on the skin, and arthralgia for two months, besides hypoesthesia and reduced muscle strength of the left leg and foot, and areas of hyperesthesia on the left foot for one month. With this clinical picture, the patient went multiple times to the emergency department and was treated with corticoids, nonsteroidal anti-inflammatory drugs, antibiotics and analgesics. She was also assessed by an infectious disease specialist and a cardiologist. She finally went to a rheumatologist, who referred her to the dermatology service.
The patient had asthma for four years, was followed by a respiratory physician and was on Montelukast, corticoid inhaler and long acting beta2-agonist. There was no history of rhinitis.
On dermatologic examination, there were erythematous, purpuric papules, with overlying erosions or crusts on the dorsum of the hand, on the index finger, and on the left elbow and foot (Figures 1 to 3 ). There was also hypoesthesia and areas of loss of 3 Cardiovascular system is affected in about 10% of cases and this involvement is the primary cause of death in patients with CSS.
Among the most important manifestations are coronary arteritis and myocarditis. 4 Although rare, central nervous system involvement is the major cause of mortality among patients. 3 About 50% of patients will present with skin changes. These include: 1) hemorrhagic lesions, such as palpable purpuras, petechiae, ecchymosis and hemorrhagic bullae, and 2) dermal or subcutaneous papules and nodules, frequently located on the scalp or distributed bilaterally over the extensor surfaces of the extremities.
Other changes that can also be observed less frequently are urticaria, erythematous macules and livedo reticularis. CSS prognosis is variable and depends on the initial extension of the disease and the organs affected. Five factors were described that are associated to a higher mortality among patients; which are: creatinine higher than 1.58mg/dL, proteinuria higher than 1 g/day, gastrointestinal involvement, central nervous system involvement and cardiomyopathy. 6 These criteria help identify the patients that need a more aggressive immunosuppressive therapy, due to the higher chance of mortality and higher frequency of relapse. Conventional treatment includes the use of corticosteroids.
For the patients that are unresponsive to corticosteroid therapy or to those that have poor prognosis features, immunosuppressive therapy with cytotoxic agents is indicated. Cyclophosphamide is the most effective cytotoxic to induce CSS remission. 7 We opted to use cyclophosphamide because the patient failed corticosteroids, that were used for months for her asthma. Besides, she already had mild cardiac systolic dysfunction. 
